Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/ijmr.IJMR_2294_20 http://scihub22266oqcxt.onion/10.4103/ijmr.IJMR_2294_20 33818480!8184065!33818480     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Indian+J+Med+Res 2021 ; 153 (1 & 2): 219-226 Nephropedia Template TP {{tp|p=33818480|t=2021. Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis |pdf=|usr=}}{{33818480}} gab.com Text Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis JO: Indian J Med Res http://www.kidney.de/pget.php?&tw=1&pmid=33818480 #FOAvip BACKGROUND & OBJECTIVES: Hydroxychloroquine (HCQ), reported to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in in vitro studies, has been recommended for prophylaxis of COVID-19 in healthcare workers (HCWs). The objective of this study was to assess short-term adverse events (AEs) of HCQ in HCWs. METHODS: This cross-sectional study among consenting HCWs taking prophylaxis and working in hospitals with COVID-19 patients used online forms to collect details of HCWs, comorbidities, prophylactic drugs used and AEs after the first dose of HCQ. Verification of dose and AEs was done by personal contact. Multivariate logistic regression analysis was done to determine the effect of age, gender and dose of HCQ on AE. RESULTS: Of the 1303 HCWs included, 98.4 per cent (n=1282) took HCQ and 66 per cent (n=861) took 800 mg as first day's dose. Among the 19.9 per cent (n=259) reporting AEs, 1.5 per cent (n=20) took treatment for AE, none were hospitalized and three discontinued HCQ. Gastrointestinal AEs were the most common (172, 13.2%), with less in older [odds ratio (OR) 0.56, 95% confidence interval (CI) 0.35-0.89], with more in females (OR 2.46, 95% CI 1.78-3.38) and in those taking a total dose of 800 mg on day one compared to a lower dose. Hypoglycaemia (1.1%, n=14), cardiovascular events (0.7%, n=9) and other AEs were minimal. INTERPRETATION & CONCLUSIONS: HCQ prophylaxis first dose was well tolerated among HCWs as evidenced by a low discontinuation. For adverse effects, a small number required treatment, and none required hospitalization. The study had limitations of convenience sampling and lack of laboratory and electrocardiography confirmation of AEs. Twit Text FOAVip Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis ????Indian J Med Res http://www.kidney.de/pget.php?&tw=1&pmid=33818480 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33818480 #FOAvip English Wikipedia <ref>{{Cite pmid|33818480}}</ref> Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis #MMPMID33818480 Faruqui AR; Xavier D; Kamat SK; Chandy SJ; Medhi B; Tripathi RK; Shetty YC; Raj JM; Kaushal S; Balakrishnan S; Atal S; Tripathi SK; Badyal DK; Dikshit H; Roy SS; Trivedi N; Chatterjee S; Desai C; Tripathi CD; Rege NN; Gupta P; Raveendran R; Kaul R; Kshirsagar NA Indian J Med Res 2021[Jan]; 153 (1 & 2): 219-226 PMID33818480show ga BACKGROUND & OBJECTIVES: Hydroxychloroquine (HCQ), reported to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in in vitro studies, has been recommended for prophylaxis of COVID-19 in healthcare workers (HCWs). The objective of this study was to assess short-term adverse events (AEs) of HCQ in HCWs. METHODS: This cross-sectional study among consenting HCWs taking prophylaxis and working in hospitals with COVID-19 patients used online forms to collect details of HCWs, comorbidities, prophylactic drugs used and AEs after the first dose of HCQ. Verification of dose and AEs was done by personal contact. Multivariate logistic regression analysis was done to determine the effect of age, gender and dose of HCQ on AE. RESULTS: Of the 1303 HCWs included, 98.4 per cent (n=1282) took HCQ and 66 per cent (n=861) took 800 mg as first day's dose. Among the 19.9 per cent (n=259) reporting AEs, 1.5 per cent (n=20) took treatment for AE, none were hospitalized and three discontinued HCQ. Gastrointestinal AEs were the most common (172, 13.2%), with less in older [odds ratio (OR) 0.56, 95% confidence interval (CI) 0.35-0.89], with more in females (OR 2.46, 95% CI 1.78-3.38) and in those taking a total dose of 800 mg on day one compared to a lower dose. Hypoglycaemia (1.1%, n=14), cardiovascular events (0.7%, n=9) and other AEs were minimal. INTERPRETATION & CONCLUSIONS: HCQ prophylaxis first dose was well tolerated among HCWs as evidenced by a low discontinuation. For adverse effects, a small number required treatment, and none required hospitalization. The study had limitations of convenience sampling and lack of laboratory and electrocardiography confirmation of AEs. |*COVID-19 Drug Treatment[MESH] |*Health Personnel[MESH] |*Hydroxychloroquine/adverse effects/therapeutic use[MESH] |COVID-19/*prevention & control[MESH] |Cross-Sectional Studies[MESH] |Female[MESH] |Humans[MESH] |Male[MESH]Safety of hydroxychloroquine in healthcare workers for COVID-19 prophy(epmc).pdf DeepDyve Pubget Overpricing